Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. Objective: To describe the design and rationale for the genetic analysis of acute and chronic cerebrovascular neuroimaging phenotypes detected on clinical MRI in patients with acu...

Full description

Bibliographic Details
Format: Article
Language:English
Published: Ovid Technologies (Wolters Kluwer Health) 2021
Online Access:https://hdl.handle.net/1721.1/134743
_version_ 1826201163256561664
collection MIT
description Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. Objective: To describe the design and rationale for the genetic analysis of acute and chronic cerebrovascular neuroimaging phenotypes detected on clinical MRI in patients with acute ischemic stroke (AIS) within the scope of the MRI-GENetics Interface Exploration (MRI-GENIE) study. Methods: MRI-GENIE capitalizes on the existing infrastructure of the Stroke Genetics Network (SiGN). In total, 12 international SiGN sites contributedMRIs of 3,301 patients with AIS. Detailed clinical phenotyping with the web-based Causative Classification of Stroke (CCS) system and genome-wide genotyping data were available for all participants. Neuroimaging analyses include themanual and automated assessments of established MRI markers. A high-throughputMRI analysis pipeline for the automated assessment of cerebrovascular lesions on clinical scans will be developed in a subset of scans for both acute and chronic lesions, validated against gold standard, and applied to all available scans. The extracted neuroimaging phenotypes will improve characterization of acute and chronic cerebrovascular lesions in ischemic stroke, including CCS subtypes, and their effect on functional outcomes after stroke. Moreover, genetic testing will uncover variants associated with acute and chronic MRI manifestations of cerebrovascular disease.Conclusions: The MRI-GENIE study aims to develop, validate, and distribute the MRI analysis platform for scans acquired as part of clinical care for patients with AIS, which will lead to (1) novel genetic discoveries in ischemic stroke, (2) strategies for personalized stroke risk assessment, and (3) personalized stroke outcome assessment.
first_indexed 2024-09-23T11:47:12Z
format Article
id mit-1721.1/134743
institution Massachusetts Institute of Technology
language English
last_indexed 2024-09-23T11:47:12Z
publishDate 2021
publisher Ovid Technologies (Wolters Kluwer Health)
record_format dspace
spelling mit-1721.1/1347432022-04-04T19:09:09Z Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. Objective: To describe the design and rationale for the genetic analysis of acute and chronic cerebrovascular neuroimaging phenotypes detected on clinical MRI in patients with acute ischemic stroke (AIS) within the scope of the MRI-GENetics Interface Exploration (MRI-GENIE) study. Methods: MRI-GENIE capitalizes on the existing infrastructure of the Stroke Genetics Network (SiGN). In total, 12 international SiGN sites contributedMRIs of 3,301 patients with AIS. Detailed clinical phenotyping with the web-based Causative Classification of Stroke (CCS) system and genome-wide genotyping data were available for all participants. Neuroimaging analyses include themanual and automated assessments of established MRI markers. A high-throughputMRI analysis pipeline for the automated assessment of cerebrovascular lesions on clinical scans will be developed in a subset of scans for both acute and chronic lesions, validated against gold standard, and applied to all available scans. The extracted neuroimaging phenotypes will improve characterization of acute and chronic cerebrovascular lesions in ischemic stroke, including CCS subtypes, and their effect on functional outcomes after stroke. Moreover, genetic testing will uncover variants associated with acute and chronic MRI manifestations of cerebrovascular disease.Conclusions: The MRI-GENIE study aims to develop, validate, and distribute the MRI analysis platform for scans acquired as part of clinical care for patients with AIS, which will lead to (1) novel genetic discoveries in ischemic stroke, (2) strategies for personalized stroke risk assessment, and (3) personalized stroke outcome assessment. 2021-10-27T20:08:56Z 2021-10-27T20:08:56Z 2017-10-01 2019-05-29T18:22:56Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/134743 en 10.1212/NXG.0000000000000180 Neurology: Genetics Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Ovid Technologies (Wolters Kluwer Health) American Academy of Neurology
spellingShingle Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study
title Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study
title_full Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study
title_fullStr Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study
title_full_unstemmed Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study
title_short Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study
title_sort design and rationale for examining neuroimaging genetics in ischemic stroke the mri genie study
url https://hdl.handle.net/1721.1/134743